Dark

Check out our API

BLCM
BELLICUM PHARMS INC
stock OTC

Inactive

Mar 4, 2024

0.0748USD-6.679%(-0.0054)6,059

Pre-market

0.00USD-100.000%(-0.08)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 26, 2022

04:05PM EST Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick Fair, President and CEO, will participate in the B. Riley Securities 2022 Virtual Oncology Conference. A corporate presentation is scheduled for Thursday, January 27, 2022 at 4 p.m. ET / 1 p.m. PT. GlobeNewswire Inc

Jan 21, 2022

01:33PM EST Bellicum Pharma Shares Quiet; Traders Circulate European Patent Register For Co.'s 'METHODS FOR INDUCING PARTIAL APOPTOSIS USING CASPASE POLYPEPTIDES' Benzinga

Dec 13, 2021

04:06PM EST Bellicum Regains Compliance With Nasdaq Continued Listing Requirements Benzinga

Dec 6, 2021

08:11AM EST Bellicum Pharmaceuticals, Inc. (BLCM) reported positive interim data from ongoing phase 1/2 GoCAR-T clinical trials, including a confirmed partial response in the first cohort of mCRPC patients treated in the clinical trial for BPX-601. RTTNews

07:37AM EST Bellicum Pharma Announces Positive Interim Data From Phase 1/2 GoCAR-T Clinical Trials RTTNews

07:32AM EST Bellicum Announces Positive Interim Data From Phase 1/2 GoCAR-T Studies, Secures $35 Million Private Placement Equity Financing Priced At Market Benzinga

07:30AM EST - Confirmed partial response observed in one patient in first cohort of metastatic castration-resistant prostate cancer (mCRPC) patients treated with BPX-601 - GlobeNewswire Inc

Nov 5, 2021

09:31AM EDT Bellicum Pharmaceuticals Q3 EPS $0.07 Up From $(0.18) YoY Benzinga

09:29AM EDT Bellicum Pharmaceuticals Inc On November 2, 2021, Nasdaq Notified The Registrant That It Had Not Regained Compliance With The Market Value Rule Benzinga

Sep 6, 2021

10:27AM EDT 5 Value Stocks In The Healthcare Sector Benzinga

Sep 3, 2021

07:30AM EDT Bellicum Pharmaceuticals to Participate in the H.C. Wainwright GlobeNewswire Inc

Sep 1, 2021

07:37AM EDT Bellicum And MD Anderson Announce Addl License Agreement For Use Of CaspaCIDe Safety Switch RTTNews

07:34AM EDT Bellicum and MD Anderson Announce Additional License Agreement for Use of CaspaCIDe Safety Switch Benzinga

07:30AM EDT Bellicum and MD Anderson Announce Additional License Agreement for GlobeNewswire Inc

Aug 12, 2021

05:22PM EDT Bellicum Pharmaceuticals Q2 EPS $(0.22) Up From $(7.81) YoY Benzinga

04:05PM EDT - Entered into a licensing agreement with two leading oncology research and treatment centers for use of CaspaCIDe safety switch technology - GlobeNewswire Inc

Jul 26, 2021

05:26PM EDT Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq GlobeNewswire Inc

Jun 28, 2021

07:34AM EDT Bellicum Pharma Enters License Agreement With UNC Lineberger And Mass General For Use Of CaspaCIDe Safety Switch RTTNews

07:31AM EDT Bellicum Enters License Agreement with UNC Lineberger and Mass General for Use of CaspaCIDe Safety Switch Benzinga

07:30AM EDT Bellicum Enters License Agreement with UNC Lineberger and Mass GlobeNewswire Inc

May 20, 2021

08:27AM EDT The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Order Flow Abounds, Voyager CEO, CMO To Depart, Decision Day For Bristol-Myers Squibb, ASCO Abstracts Move Stocks Benzinga

May 17, 2021

07:39AM EDT Bellicum Pharmaceuticals Q1 EPS $(1.12) Down From $1.09 YoY Benzinga

07:30AM EDT Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial results for the first quarter 2021 and provided an operational update. GlobeNewswire Inc

Apr 15, 2021

10:11AM EDT Bellicum Pharmaceuticals Files U.S. Patent Application #20210107966 'NATURAL KILLER CELL PRODUCTS AND METHODS' Benzinga

Mar 31, 2021

07:41AM EDT The Daily Biotech Pulse: Pfizer Vaccine 100% Effective In Adolescents, Equillium Readout, Amgen Goes Shopping, Achilles IPO Benzinga

Mar 30, 2021

04:12PM EDT Bellicum Pharmaceuticals Q4 EPS $0.98 Beats $(1.06) Estimate Benzinga

04:05PM EDT Enrolled first patient in Phase 1/2 clinical trial for BPX-603 in solid tumors that express HER2 GlobeNewswire Inc

08:06AM EDT The Daily Biotech Pulse: Wave Life Sciences Pulls Plug On 2 Assets, Amarin's Vascepa Snags European Approval, Biocept Jumps On Earnings Benzinga

04:04AM EDT Earnings Scheduled For March 30, 2021 Benzinga

Mar 27, 2021

01:01PM EDT The Week Ahead In Biotech (March 28-April 3): Acadia's Dementia Drug Update, Clinical Readouts, Few Earnings In Holiday-Shortened Week Benzinga

Mar 23, 2021

04:05PM EDT Bellicum to Report Fourth Quarter and Full Year 2020 Financial GlobeNewswire Inc

Mar 4, 2021

08:39AM EST Bellicum Shares Are Trading Higher On First Reported Positive Clinical Use Of iC9 Safety Switch Benzinga

07:30AM EST Bellicum Announces First Reported Use of CaspaCIDe GlobeNewswire Inc

Feb 8, 2021

08:31AM EST Ponce Therapeutics Inc. Commences First R & D Program in Anti-Aging Products PR Newswire

Jan 29, 2021

07:45AM EST The Daily Biotech Pulse: Novavax Vaccine Readout, Clinical Hold On Bellicum Study Lifted, Lilly Earnings, NLS Pharma IPO Benzinga

Jan 28, 2021

04:26PM EST Bellicum Says FDA Lifted Clinical Hold On BPX-601 Phase 1/2 Clinical Trial RTTNews

04:11PM EST Bellicum Reports FDA Lifted Clinical Hold on BPX-601 Phase 1/2 Clinical Trial Benzinga

Jan 11, 2021

06:14AM EST Ikarian Capital Reports 9.9% Passive Stake in Bellicum Pharmaceuticals in 13G Filing as of Dec 24, 2020 Benzinga

Dec 11, 2020

08:11AM EST The Daily Biotech Pulse: Pfizer-BioNTech Receive FDA Panel Backing, Sanofi-GSK Disclose Delay In Vaccine Program, 4 Biotechs To Debut On Wall Street Benzinga

Dec 10, 2020

07:42AM EST The Daily Biotech Pulse: Key Vaccine Adcom Review For Pfizer-BioNTech, Puma, Immutep, G1 Rally On Breast Cancer Conference Presentations Benzinga

07:38AM EST Bellicum Enrolls And Apheresis Of First Patient In Phase 1/2 Clinical Trial For BPX-603 RTTNews

07:30AM EST Bellicum Pharma Reports Enrollment Of First Patient In Phase 1/2 Trial Of BPX-603 Benzinga

07:30AM EST Bellicum Enrolls First Patient in Phase 1/2 Clinical GlobeNewswire Inc

Dec 7, 2020

07:31AM EST Bellicum Reports Clinical Hold Placed on BPX-601 Phase 1/2 Clinical Trial Benzinga

07:30AM EST Bellicum Reports Clinical Hold Placed on BPX-601 Phase 1/2 GlobeNewswire Inc

Nov 10, 2020

08:40AM EST The Daily Biotech Pulse: Lilly's COVID-19 Antibody Treatment Approved For Emergency Use, Supernus Faces Twin Regulatory Setbacks, Revance, Arena Flunk Midstage Studies Benzinga

Nov 6, 2020

07:47AM EST The Daily Biotech Pulse: Novartis Drug Flunks COVID-19 Study, Molecular Templates' Blood Cancer Study Placed On Partial Hold Benzinga

Nov 5, 2020

05:14PM EST Bellicum Pharmaceuticals Q3 EPS $(0.18) Up From $(0.68) YoY Benzinga

Nov 4, 2020

08:21AM EST The Daily Biotech Pulse: Alzheimer's Conference Underway, Biogen's Aducanumab Briefing Doc, Supernus Earnings Benzinga

Nov 3, 2020

08:26PM EST Bellicum Pharmaceuticals Announces Closing of $25.0 Million GlobeNewswire Inc

Oct 30, 2020

03:15PM EDT Mid-Afternoon Market Update: Rogers Jumps Following Upbeat Q3 Results; Pitney Bowes Shares Plunge Benzinga

12:08PM EDT Mid-Day Market Update: Nasdaq Tumbles Over 300 Points; Acadia Healthcare Shares Gain After Q3 Results Benzinga

10:18AM EDT Mid-Morning Market Update: Markets Open Lower; Honeywell Earnings Beat Estimates Benzinga

10:06AM EDT Benzinga's Top Upgrades, Downgrades For October 30, 2020 Benzinga

08:09AM EDT The Daily Biotech Pulse: Novavax Vaccine Data, Axovant Flags Delay In Parkinson's Study, 2 Biotechs Make Wall Street Debuts Benzinga

06:15AM EDT Wells Fargo Downgrades Bellicum Pharmaceuticals to Equal-Weight, Announces $4.5 Price Target Benzinga

Oct 29, 2020

05:22PM EDT Bellicum Prices At-The-Market Offering Of ~4.15M Shares At $6.025/Share Benzinga

05:20PM EDT UPDATE: Bellicum To Cut Staff By 79% From 68 To 14 Full-Time Employees By End Of 2020 Benzinga

05:20PM EDT Bellicum To Focus On Clinical Development Of BPX-601, BPX-603, Pause BCMA GoCAR-NK Program, Discontinue Discovery Research, New Product Development Benzinga

05:19PM EDT Bellicum Sees Beginning Patient Enrollment For BPX-601 Benzinga

05:18PM EDT Bellicum Implements Restructuring Plan, Including Reduction In Staff, To Focus Efforts On Clinical GoCAR-T Product Candidates Benzinga

05:17PM EDT Bellicum Reports Findings From First 4 Patients In BPX-601 Trial Showed Evidence Of Rimiducid-Mediated CAR-T Cell Activation, Clinically Meaningful Efficacy Was Not Observed Benzinga

05:05PM EDT Bellicum Pharma Shares Halted News Pending Benzinga

Sep 30, 2020

04:10PM EDT Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Benzinga

04:08PM EDT Bellicum Reports Inducement Grants Under Nasdaq Listing Rule GlobeNewswire Inc

Sep 28, 2020

07:30AM EDT Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that management will participate in two upcoming virtual conferences. GlobeNewswire Inc

Sep 15, 2020

10:31AM EDT Shares of Bellicum Pharmaceuticals Inc. (BLCM), a clinical-stage biopharmaceutical company, gained over 25% on Tuesday morning despite no stock-related news to drive the shares. RTTNews

Sep 2, 2020

07:30AM EDT Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that management will participate in two upcoming virtual investor conferences. GlobeNewswire Inc

Aug 31, 2020

04:11PM EDT Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Benzinga

04:08PM EDT Bellicum Reports Inducement Grants Under Nasdaq Listing Rule GlobeNewswire Inc

Aug 6, 2020

05:43PM EDT Bellicum Pharmaceuticals Q2 EPS $(8.55) Benzinga

05:10PM EDT Bellicum Pharmaceuticals Q2 EPS $(8.55) May Not Compare To $(3.33) Estimate Benzinga

Jul 31, 2020

04:09PM EDT Bellicum Reports Inducement Grants Under Nasdaq Listing Rule GlobeNewswire Inc

Share